Ruxolitinib, a potent Janus kinase 1/2 inhibitor, led to fast and durable improvements in splenomegaly and disease-related symptoms in the two 2 stage III COMFORT research. ruxolitinib had extended success compared with sufferers who received placebo or greatest obtainable therapy [threat proportion=0.65; 95% self-confidence period (95%CI): 0.46C0.90; V617F mutation position, base-line palpable spleen duration (per… Continue reading Ruxolitinib, a potent Janus kinase 1/2 inhibitor, led to fast and